

(1, 0, 1).

117. The composition of claim 114 or 116 wherein the protein is bovine serum albumin, polylysine, or keyhole limpet hemocyanin.
118. The composition of claim 114 or 116 wherein the immunological adjuvant is bacteria or liposomes.

B. In the Specification:

Please cancel the amendment to the paragraph starting at line 6 and ending at line 12 on page 1, detailed in the Preliminary Amendment filed April 12, 2001.

Please delete the paragraph on page 1, starting at line 6 and ending at line 12, and replace it with the following amended paragraph:

CS This application is a Divisional Application filed under 37 C.F.R. § 1.53(b) of Application Serial Number 09/042,280, filed January 13, 1998, which further claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application Serial No. 60/034,950, filed January 13, 1997; the entire contents of each of these applications are hereby incorporated by reference into this application. This invention was made with government support under grants CA-28824-18, GM-15240-02, GM-16291-01, HL-25848-14 and AI-16943 from the National Institutes of Health. Additionally, the present invention was supported in part by a fellowship from the United States Army to Hyun Jin Kim (DAMD 17-97-1-7119). Accordingly, the U.S. Government has certain rights in the invention.

Please replace the paragraph on page 12, starting at line 21 and ending at line 32 with the following amended paragraph:

C6 This antigen has been claimed to be a highly specific marker for malignancy and pre-malignancies involving colonic adenocarcinoma. The nonasaccharide character of 1 (Figure 1) is unique from a structural standpoint. The crystallographically derived presentation of the monoclonal antibody BR 96 bound to a Le^y tetrasaccharide glycoside has been reported. (Jeffery, P.D.; Bajorath, J.; Chang, C.Y.; Dale, Y.; Hellstrom, I.; Hellstrom, E.K.; Sheriff, S., *Nature Structural Biology*, 1995, 2, 466.) The structure of the BR96:Le^y complex suggested that this